• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TENIPOSIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • TENIPOSIDE chembl:CHEMBL452231 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    VM-26
    VUMON
    NSC-122819
    TENIPOSIDE
    VM26
    EPIDOPHYLLOTOXIN
    TENIPOSIDUM
    4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-2-THENYLIDENE-BETA-D-GLUCOPYRANOSIDE)
    TENIPOSIDO
    TENIPOSID
    VUMON®
    TÉNIPOSIDE
    ISOSULFAN BLUE
    rxcui:10362
    chemidplus:29767-20-2
    chembl:CHEMBL452231
    pubchem.compound:452548
    drugbank:00444

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 1992
    FDA Approval 1992
    Drug Class small molecule
    Drug Indications Antineoplastic Agents
    (4 More Sources)

    Publications:

    Winter et al., 1998, Synergy of CD95 ligand and teniposide: no role of cleavable complex formation and enhanced CD95 expression., Eur. J. Pharmacol.
    Brown et al., 1998, Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease., Am. J. Clin. Pathol.
    Faure et al., 1996, [Topoisomerases: therapeutic value]., Ann Pharm Fr
    Umanskaya et al., Inhibition of DNA topoisomerase II in living cells stimulates illegitimate recombination., Dokl. Biochem. Biophys.
    de Lucio et al., 2005, Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha., Cancer Sci.
    Winnicka et al., Cardiac glycosides in cancer research and cancer therapy., Acta Pol Pharm
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Uesaka et al., 2007, Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity., J. Neurooncol.
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Wang et al., 1998, Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53., Cancer Res.
    Borgnetto et al., 1996, Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility., Cancer Res.
    Weller et al., 1998, Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses., Int. J. Cancer
  • TENIPOSIDE   NUP50

    Interaction Score: 15.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • TENIPOSIDE   H2AW

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8620504


    Sources:
    NCI

  • TENIPOSIDE   TOP2A

    Interaction Score: 1.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction DNA topoisomerase II inhibitor

    PMIDs:
    9426516 8702194 16480143 16271071 17514873 11752352 17361331


    Sources:
    TdgClinicalTrial ChemblInteractions NCI TEND

  • TENIPOSIDE   FAS

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9543255


    Sources:
    NCI

  • TENIPOSIDE   TOP2B

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction DNA topoisomerase II inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • TENIPOSIDE   BCL2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9842975


    Sources:
    NCI

  • TENIPOSIDE   ABCC1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9865734


    Sources:
    NCI

  • TENIPOSIDE   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: TENIPOSIDE

    • Version: 01-August-2011

    Alternate Names:
    TENIPOSIDE Primary Drug Name

    Drug Info:
    Year of Approval 1992
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: TENIPOSIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents
    Drug Class small molecule
    FDA Approval 1992

    Publications:

  • NCI: VM-26

    • Version: 14-September-2017

    Alternate Names:
    C857 NCI drug code

    Drug Info:

    Publications:
    Wang et al., 1998, Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53., Cancer Res.
    Borgnetto et al., 1996, Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility., Cancer Res.

  • NCI: TENIPOSIDE

    • Version: 14-September-2017

    Alternate Names:
    C857 NCI drug code

    Drug Info:

    Publications:
    Winter et al., 1998, Synergy of CD95 ligand and teniposide: no role of cleavable complex formation and enhanced CD95 expression., Eur. J. Pharmacol.
    Gorczyca et al., 1992, Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide., Cancer Res.
    Brown et al., 1998, Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease., Am. J. Clin. Pathol.

  • PharmGKB: teniposide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics

  • TTD: Teniposide

    • Version: 2020.06.01

    Alternate Names:
    D01DBQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL452231

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL452231

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21